PSNews – The National Ethics Council for Biomedical Research under the Ministry of Health approved phase 1 and phase 2 human trials of the Nanocovax COVID-19 vaccine produced by NANOGEN Company in collaboration with the Military Medical University.
The National Ethics Council for Biomedical Research also approved the plan to select volunteers for the first phase of the clinical trials.
On December 10, the Military Medical University started to select volunteers for phase 1 trials.
The first phase of human trials will need 60 people aged between 18 and 50 and in a good health condition. The selected volunteers will be divided randomly in to 3 groups.
In the first phase, all volunteers will receive two intramuscular injections of the vaccine, and the interval of the two injections is 28 days.
The first vaccine injection drive will be conducted on December 17.
After about two to four weeks, they will be tested for COVID-19 antibodies and move to the second phase, which is set to begin in January next year with about 400 volunteers aged 18 to 60.
The third stage will cover 3,000 people between 12 and 70 years of age and begin in March.
The Ministry of Health is hoping to have a commercially-viable COVID-19 vaccine by the fourth quarter of 2021.
NANOGEN’s OVID-19 19 vaccine Nanocovax is expected to be priced at a maximum of VND500,000 ($21.62) per dose.
By An Nhien
Apart from Nanocovax, Vietnam has several other COVID-19 candidate vaccines being developed, by Vabiotech, Polyvac, and the Institute of Vaccines and Medical Biologicals.